Reverse phase protein microarrays advance to use in clinical trials.
Reverse phase protein microarrays advance to use in clinical trials.
复制标题
DOI:
10.1016/j.molonc.2010.09.003
复制
发表时间:
2010-12
影响因子:
6.6
通讯作者:
Espina V
中科院分区:
文献类型:
--
作者:
Mueller C;Liotta LA;Espina V
Individualizing cancer therapy for molecular targeted inhibitors requires a new class of molecular profiling technology that can map the functional state of the cancer cell signal pathways containing the drug targets. Reverse phase protein microarrays (RPMA) are a technology platform designed for quantitative, multiplexed analysis of specific phosphorylated, cleaved, or total (phosphorylated and non-phosphorylated) forms of cellular proteins from a limited amount of sample. This class of microarray can be used to interrogate tissue samples, cells, serum, or body fluids. RPMA were previously a research tool; now this technology has graduated to use in research clinical trials with clinical grade sensitivity and precision. In this review we describe the application of RPMA for multiplexed signal pathway analysis in therapeutic monitoring, biomarker discovery, and evaluation of pharmaceutical targets, and conclude with a summary of the technical aspects of RPMA construction and analysis.
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-08-3293
发表时间:
2009-06-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Agarwal R;Gonzalez-Angulo AM;Myhre S;Carey M;Lee JS;Overgaard J;Alsner J;Stemke-Hale K;Lluch A;Neve RM;Kuo WL;Sorlie T;Sahin A;Valero V;Keyomarsi K;Gray JW;Borresen-Dale AL;Mills GB;Hennessy BT
通讯作者:
Hennessy BT
影响因子:
64.5
作者:
Azam, M;Latek, RR;Daley, GQ
通讯作者:
Daley, GQ
影响因子:
64.8
作者:
Alizadeh, AA;Eisen, MB;Staudt, LM
通讯作者:
Staudt, LM
影响因子:
--
作者:
Davuluri, Geetanjali;Espina, Virginia;Glaser, Bert M.
通讯作者:
Glaser, Bert M.
影响因子:
7.3
作者:
Becker, K-F;Schott, C.;Hoefler, H.
通讯作者:
Hoefler, H.